Note 15 - Segments

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Segments

NOTE 15 SEGMENTS

We manage our operations in two reportable segments - pharmaceutical and diagnostics. The following is a brief description of our reportable segments and a description of business activities conducted by our corporate operations.

Pharmaceutical — this segment consists of our operations in Chile, Mexico, Ireland, Israel, Spain, Brazil, and Uruguay, Rayaldee product sales, NGENLA royalty and profit-sharing sales, and our pharmaceutical research and development.

Diagnostics — this segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations.

To provide greater transparency into the factors affecting segment profitability, the Company discloses significant expense categories for each reportable segment in the tables below. Our CODM is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. Our CODM may discuss and review financial information at the Pharmaceutical and Diagnostic operating segment level. The CODM uses segment information to evaluate segment profitability, monitor trends, identify risks and opportunities, allocate resources (such as capital expenditures and R&D funding), and set strategic priorities (including new product development and market expansion). These expenses, along with segment revenue, are used to calculate gross margin, a key profitability metric that the CODM uses to assess segment performance. In computing operating income, none of the following items have been included: interest expense, other non-operating income and expenses, and income taxes. Segment operating income (expense) is total revenue, less cost of revenue and operating expenses relative to each segment. There are no significant inter-segment sales, nor is there any inter-segment allocation of interest expense or income taxes.

The following are descriptions of the significant expense categories included in the segment reporting tables below:

For the pharmaceutical segment:

•Cost of product revenue: Represents the direct costs of manufacturing and distributing pharmaceutical products, including raw materials, manufacturing overhead, and distribution costs.

•Selling, general and administrative (SG&A) expenses: Encompasses operating expenses such as salaries, marketing and advertising costs, and administrative overhead.

•Research and development (R&D) expenses: Incurred in developing new pharmaceutical products, including costs related to research, clinical trials, and regulatory approvals.

•Intangible asset amortization: Represents the periodic expensing of acquired intangible assets, such as patents and licenses.

•Depreciation: Relates to the depreciation of property, plant, and equipment used in the segment's operations.

For the diagnostics segment:

•Cost of service revenue: Includes the direct costs of providing diagnostic testing services, such as laboratory supplies, equipment costs, and labor costs.

•Selling, general and administrative (SG&A) expenses: Similar to the Pharmaceuticals segment, includes salaries, marketing expenses, and administrative overhead.

•Research and development (R&D) expenses: Incurred in developing new diagnostic products and services, including costs related to research, clinical studies, regulatory submissions, and new technology development.

•Intangible asset amortization: Represents the periodic expensing of acquired intangible assets, such as intellectual property and customer relationships.

•Depreciation: Relates to the depreciation of property, plant, and equipment used in the segment's operations.

The tables below present information about reported segments, unallocated corporate operations as well as geographic information for the three and six months ended June 30, 2025 and 2024:

	For the three months ended June 30,						For the six months ended June 30,
(In thousands)	2025			2024			2025			2024
Revenue from services:
Pharmaceutical	$	—		$	—		$	—		$	—
Diagnostics		101,101			129,395			203,945			256,286
Corporate		—			—			—			—
	$	101,101		$	129,395		$	203,945		$	256,286
Revenue from products:
Pharmaceutical	$	40,743		$	40,485		$	75,585		$	78,532
Diagnostics		—			—			—			—
Corporate		—			—			—			—
	$	40,743		$	40,485		$	75,585		$	78,532
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	14,963		$	12,306		$	27,229		$	21,054
Diagnostics		—			—			—			—
Corporate		—			—			—			—
	$	14,963		$	12,306		$	27,229		$	21,054
Cost of revenue:
Pharmaceutical	$	25,022		$	23,455		$	47,836		$	45,199
Diagnostics		82,383			107,078			166,901			216,952
Corporate		—			—			—			—
	$	107,405		$	130,533		$	214,737		$	262,151
Gross margin:
Pharmaceutical	$	30,684		$	29,336		$	54,977		$	54,387
Diagnostics		18,718			22,317			37,044			39,334
Corporate		—			—			—			—
	$	49,402		$	51,653		$	92,021		$	93,721
Selling, general and administrative:
Pharmaceutical	$	13,197		$	14,062		$	25,907		$	29,103
Diagnostics		33,369			44,502			71,325			90,262
Corporate		13,031			10,257			21,451			19,623
	$	59,597		$	68,821		$	118,683		$	138,988
Research and development:
Pharmaceutical	$	29,778		$	23,686		$	60,016		$	44,933
Diagnostics		484			386			1,022			1,052
Corporate		80			10			145			35
	$	30,342		$	24,082		$	61,183		$	46,020
Amortization of intangible assets:
Pharmaceutical	$	16,415		$	16,408		$	32,525		$	32,851
Diagnostics		3,029			4,012			6,779			9,005
Corporate		—			—			—			—
	$	19,444		$	20,420		$	39,304		$	41,856
Segment operating loss:
Pharmaceutical	$	(28,706	)	$	(24,820	)	$	(63,470	)	$	(52,500	)
Diagnostics		(18,164	)		(26,583	)		(42,082	)		(60,985	)
Corporate		(13,111	)		(10,267	)		(21,596	)		(19,658	)
	$	(59,981	)	$	(61,670	)	$	(127,148	)	$	(133,143	)

	For the three months ended June 30,				For the six months ended June 30,
	2025		2024		2025		2024
Depreciation and amortization:
Pharmaceutical	$	18,142	$	17,905	$	35,930	$	35,856
Diagnostics		4,885		6,250		10,584		14,118
Corporate		—		—		—		—
	$	23,027	$	24,155	$	46,514	$	49,974
Revenues:
United States	$	114,884	$	141,717	$	231,091	$	277,759
Ireland		11,742		9,842		17,221		19,065
Chile		16,003		17,602		30,535		32,491
Spain		6,724		5,872		13,164		11,531
Israel		139		441		212		601
Mexico		6,297		5,908		12,526		12,991
Other		1,018		804		2,010		1,434
	$	156,807	$	182,186	$	306,759	$	355,872

Segment assets for the two reportable segments in which we operate are shown in the following tables. Corporate assets are principally cash and are not allocated to an operating segment. Identifiable assets by segment are those assets that are used in our operations in each segment. The accounting policies of the segments are the same as those described in Note 3 summary of significant accounting policies.

	June 30,		December 31,
(In thousands)	2025		2024
Assets:
Pharmaceutical	$	1,343,706	$	1,359,270
Diagnostics		476,218		493,898
Corporate		153,065		347,044
	$	1,972,989	$	2,200,212
Goodwill:
Pharmaceutical	$	320,743	$	309,545
Diagnostics		163,442		219,707
	$	484,185	$	529,252

No customer represented more than 10% of our total consolidated revenue for the six months ended June 30, 2025 and 2024. As of June 30, 2025 and December 31, 2024, no customer represented more than 10% of our accounts receivable balance.